Eli Lilly +7% premarket after $7.54 EPS vs $6.67 and forecasting 2026 profit $33.50‑$35 on strong weight‑loss drug demand

Source: [https://finance.yahoo.com/news/eli-lilly-sees-2026-profit-115421218.html](https://finance.yahoo.com/news/eli-lilly-sees-2026-profit-115421218.html)

>Eli Lilly forecast 2026 profit above Wall Street estimates on ​Wednesday, betting on surging demand for ‌its obesity drugs as the world's most valuable ‌drugmaker prepares to launch its oral weight-loss pill later this year.

>Shares of the company rose nearly 7% in premarket trading.

>Lilly last ⁠year became the ‌first pharmaceutical company to hit a $1 trillion valuation, driven by the ‍popularity of its blockbuster weight-loss drug, Zepbound, and a rapidly expanding obesity market that is shifting ​toward cash-pay options and telehealth channels.

>Lilly's ‌upbeat outlook stands in sharp contrast to that of rival Novo Nordisk, which has warned of "unprecedented" price pressures in 2026 after rattling investors with a forecast for a ⁠steep sales drop this ​year.

>For the reported quarter, ​the drugmaker reported a profit of $7.54 per share. Analysts were expecting $6.67, according ‍to data ⁠compiled by LSEG.

>Lilly expects to earn $33.50 to $35 per share on an adjusted basis ⁠this year, above analysts' average estimate of $33.23 per ‌share.

https://preview.redd.it/wq0anl6yxghg1.png?width=1578&format=png&auto=webp&s=05d47cf49f4e8beba4f2f94e2f1f31b0de080e3f